Antithrombotika zur Prophylaxe der Begleitthrombosen bei infraklavikulären Vena-Cava-Kathetern

Fassolt, A; Brändli, F; Braun, Ueli

doi:10.1159/000220889

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study provides no information on the value of prophylactic treatment (dextran 70, LDH) in reducing CVC-induced thrombosis. In patients undergoing operation, Fassolt and Braun [6] found no difference in major thrombosis developing around CVC between patients receiving low-dose heparin (5,000 IU twice daily) and a control group without heparin. In a similar comparison with dextran 70, Brfindli and Fassolt [7] found a 16% incidence of CVC-induced thrombosis in the treated group and 36% in the controls.…”

Section: Discussionmentioning

confidence: 95%

Thromboembolic complications from central venous catheters: A comparison of three catheter materials

et al. 1983

View full text Add to dashboard Cite

In this comparative study of catheter materials used in central venous catheterization (CVC) into large veins, the overall frequency of CVC‐induced thrombosis was 12%. A 20% incidence of CVC‐induced thrombosis with siliconized polyethylene catheter, 9% with Teflon® catheter, and 6% with heparinized polyethylene catheter was seen. Thrombosis thus was significantly less common with Teflon® and heparinized polyethylene than with siliconized polyethylene (p<0.05). Repeat arm phlebography was performed in 15 patients and revealed no late formation or progression of thrombosis. Pulmonary embolism appeared in 2 patients and was fatal in one of them.

show abstract

Section: Discussionmentioning

confidence: 95%

Thromboembolic complications from central venous catheters: A comparison of three catheter materials

et al. 1983

View full text Add to dashboard Cite

show abstract

“…The available information supports this practice. [169][170][171][172][173][174][175][176][177] Umbilical arterial lines: The current practice of using low dose UFH infusions was evaluated in a metaanalysis in newborns. 169 Patency, which is likely linked to the presence of local TEs, was prolonged by the use of low doses of UFH.…”

Section: Guidelines For Antithrombotic Agentsmentioning

confidence: 99%

Thromboembolic Disease and Antithrombotic Therapy in Newborns

Andrew¹,

Monagle²,

deVeber³

et al. 2001

Hematology

View full text Add to dashboard Cite

This update uses an evidence based approach to analyze and present the epidemiology of neonatal thrombosis, etiologies, currently used techniques for diagnosis with their limitations, and current therapeutic approaches. In addition, the approaches to both prevention and optimal therapies are discussed.In Section I Dr. Paul Monagle addresses the epidemiology of neonatal thrombosis outside of the central nervous system in both arterial and venous locations, and those that occur in utero. The specific contributions of catheters and congenital prothrombotic disorders are delineated. Dr. Monagle also describes currently used techniques for the diagnosis of thrombotic events as well as their limitations and the current therapeutic approaches.In Section II, Dr. Gabrielle deVeber reviews the epidemiology of neonatal thrombosis within the central nervous system, in both arterial and venous locations and those that occur in utero. The neurological presentation, risk factors including congenital prothrombotic disorders, anatomical distribution, diagnostic tests, use of antithrombotic therapy and neurologic outcome of neonates with either sinovenous thrombosis or arterial ischemic stroke are discussed.In Section III, Dr. Anthony Chan reviews the current approaches to the prevention and treatment of neonatal thrombosis. Information on the differences in the response of neonates compared to adults to antithrombotic therapy and new approaches to the prevention and treatment of thrombosis in neonates are emphasized.Thromboembolic events (TEs) during childhood are increasing in their frequency and severity, and occur in children surviving previously life-threatening primary diseases. Newborns comprise the largest group of children developing TEs. This paper discusses the epidemiology, diagnostic tests, acquired and congenital prothrombotic risk factors, long-term outcomes, and antithrombotic therapy for the management of TEs in newborns. Due to the unique features and the significance of TEs in the central nervous system (CNS), sinovenous thrombosis (SVT) and arterial ischemic stroke (AIS) will be considered separately; cerebrovascular lesions in premature infants will not be discussed.In preparation for this manuscript, comprehensive Medline reviews were performed to identify all relevant publications, which were analyzed based upon the study design; results of studies with stronger designs were given more influence in the analysis. The striking features of this review were the deficiencies in our knowledge with respect to appropriate diagnostic strategies, optimal therapy for newborns with TEs, and the contribution of congenital prothrombotic disorders. Well-designed trials are required to improve our ability to care for neonates with TEs.

show abstract

“…A Medline search identified ten clinical trials assessing heparin in CVLs. [39][40][41][42][43][44][45][46][47][48] Four trials showed that heparin is associated with a strong trend for reducing CVL-related fibrin sheath formation. [45][46][47][48] Six trials assessed the impact of heparin on partial or total occlusion of vascular flow and that heparin decreased CVL-related thrombosis.…”

Section: Central Venous Linesmentioning

confidence: 99%

“…[45][46][47][48] Six trials assessed the impact of heparin on partial or total occlusion of vascular flow and that heparin decreased CVL-related thrombosis. [41][42][43][44]46,48 Together these data suggest that heparin prophylaxis should be strongly considered for the preservation of CVL patency and perhaps reduce the risk of associated TEs.…”

Section: Central Venous Linesmentioning

confidence: 99%

Heparin Therapy in Pediatric Patients

Sutor¹,

Massicotte²,

Leaker³

et al. 1997

Semin Thromb Hemost

View full text Add to dashboard Cite

Advances in tertiary care pediatrics have resulted in heparin being one of the most frequently prescribed drugs in children's hospitals. Heparin is essential for cardiopulmonary bypass, extracorporeal membrane oxygenation, renal dialyses, maintenance of patency of venous and arterial catheters, and treatment of thromboembolic events. Currently, protocols validated in adults are used for children. However, optimal use of heparin in pediatric patients will likely differ from adults because of age-dependent physiologic and pathologic differences in hemostasis that influence the activities of heparin. The following review summarizes the influence of age on heparin anticoagulant activities, and pharmacokinetics. The indications, monitoring, therapeutic range, factors influencing dose-response relationships, and side effects of heparin therapy in pediatric patients are discussed. Finally the current and future indications for low-molecular-weight heparins in pediatric patients are summarized. Multi-centered, international clinical trials are urgently needed to assess and optimize the use of heparin in pediatric patients in a variety of clinical settings. Until these studies are completed, recommendations for adults provide guidelines for children.

show abstract

Antithrombotika zur Prophylaxe der Begleitthrombosen bei infraklavikulären Vena-Cava-Kathetern

Cited by 3 publications

References 0 publications

Thromboembolic complications from central venous catheters: A comparison of three catheter materials

Thromboembolic complications from central venous catheters: A comparison of three catheter materials

Thromboembolic Disease and Antithrombotic Therapy in Newborns

Heparin Therapy in Pediatric Patients

Contact Info

Product

Resources

About